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Contrast-induced nephropathy (CIN) has been extensively studied since the 1950s due, in part, to its devastating adverse
events. The intellectual push for additional investigation into pathogenesis and prevention has heightened in recent years
due to increased utilization of contrast enhanced imaging studies. Lack of a universal CIN definition and varied
glomerular filtration rate markers have resulted in a varied reported incidence. Risk assessment and risk reduction
strategies have evolved over the past several years. Current evidence supports volume supplementation before the
administration of intravascular contrast to reduce the hazard of CIN. Other strategies to reduce the risk of CIN,
including low osmolar contrast media, N-acetylcysteine, and intrarenal fenoldopam therapy, have variable levels of
evidence, and further randomized trials are necessary. ( J Vasc Surg 2011;54:575-9.)
o
r
d
a
r
I
G
a
o
f
a
r
t
i
i
c
t
w
s
u
l
a
s
s
i
i
h
r
i
C
D
iContrast-induced nephropathy (CIN) is the sudden de-
terioration of renal function resulting from intravenous (IV)
or intra-arterial (IA) administration of iodinated contrast me-
dia (CM).1 Bartels and colleagues first described CIN in
1954.2 Since that report, there has been an increased inci-
dence in CIN from the mid-1970s, corresponding with an
increase in procedures utilizing contrast administration.1 Var-
ious definitions of CIN exist in the literature, including a
serum creatinine (SCr) increase of0.5mg/dL, an estimated
glomerular filtration rate (eGFR) decrease of 25%, a SCr
increase 25%, or the composite, occurring 48 to 72 hours
after contrast exposure.3,4 Limitations in evaluation occur
because SCr is not only determined by GFR but also by
hydrational and nutritional status, proximal tubular function
and other factors.3 CIN is the third most common cause of
hospital-acquired renal failure.
Currently, the reported incidence of CIN ranges from 0%
to50%.Wide reporting variability results fromdifferences in
the presence or absence of risk factors (such as underlying
chronic kidney disease), the definition utilized, the amount
and type of CM, the utilization of prospective vs retrospective
reporting, the timing of SCr measurement, the type of eGFR
marker used, and the type of radiologic procedure.1,4
This report aims to review the evidence published to
date relating to CIN: pathogenesis, evaluation, reporting
standards, and prevention. In addition, further areas of
investigation are identified.
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doi:10.1016/j.jvs.2011.04.047Pathogenesis. There are several proposed mechanisms
f the pathogenesis of CIN (Fig). Two major theories are
enal vasoconstriction resulting in medullary hypoxemia (me-
iated by alterations in nitric oxide [NO], endothelin, or
denosine), and the direct cytotoxic effects of CM.
Risk assessment. Mehran and colleagues developed a
isk-profiling score for IA contrast administration (Table
)5 based upon amount of contrast administered, baseline
FR, hemodynamic instability, congestive heart failure,
ge, anemia, and diabetes. Four categories of risk are based
n the sum of the points. The incidence of CIN increases
rom 8% to 57% as risk category increases; risk also increases
s GFR falls below 60 mL/min/1.73 m2. Other specific
isk factors for CIN are IV CM administration, and inpa-
ient vs outpatient setting.6 The Dartmouth Dynamic Reg-
stry (DDR), a large prospective, clinical, consecutive reg-
stry of patients having diagnostic or interventional
ardiovascular catheterization, found that renal dysfunc-
ion (0.5 mg/dL absolute increase in SCr) was associated
ith older age, female gender, increased comorbidities,
evere coronary disease, baseline renal insufficiency, and
rgent interventions.7 The Mehran risk score was calcu-
ated for each of three groups: no renal dysfunction (aver-
ge core 5.9  2.8); transient renal dysfunction (average
core 6.8  2.7); and persistent renal dysfunction (average
core 6.3  2.8). Renal dysfunction was associated with
ncreased risk for major cardiac events, in-hospital mortal-
ty, and new onset of dialysis dependent renal failure during
ospitalization.7 Notably, both transient and persistent
enal dysfunction were associated with a twofold-threefold
ncreased risk of reduced overall survival.
IN PREVENTION STRATEGIES
ata collection and synthesis
Several strategies have been proposed to prevent CIN
n high-risk patients. Data on the different methodologies
as obtained through searches of theMEDLINE database.
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trol trials comparing CIN prevention strategies.
CIN prevention: Data overview and results
Hydration. Volume supplementation has been a cor-
nerstone in the prevention of CIN.8 Several studies have
compared hydration protocols and their effectiveness in
preventing CIN (Table II). Despite an early belief that
hydration combined with diuretics would be useful in CIN
prevention, studies have shown that furosemide and man-
nitol increase rather than reduce CIN risk.9
Taylor et al compared CIN rate for inpatient vs outpa-
tient hydration protocols. The outpatient protocol was
comparable to the inpatient protocol in preventing CIN.
They concluded that hospital admission for IV hydration is
unnecessary in patients with mild-moderate renal disease
undergoing contrast exposure.10 Trivedi et al compared IV
and oral hydration strategies and found that patients receiv-
ing IV fluids for 12 hours preprocedure and 12 hours
postprocedure had a much lower incidence of CIN than
Fig. Putative pathogenetic mechanisms of contrast-indu
renal vasoconstriction and the cytotoxicity of contrast m
induced release of endothelin and adenosine and by the h
are decreased by way of depletion of NO synthesis cof
substrates such as L-arginine, and the interference with
imbalance between vasoconstrictors and vasodilators lea
dysfunction.30 N-acetylcysteine (NAC) and fenoldopam
thus reversing renal vasoconstriction, and fenoldopam
mitochondrial function of renal cells, resulting in the gen
an antioxidant and sodium bicarbonate alkalinizes urinepatients who received oral hydration.11 HBader et al found that in patients with normal renal
unction, IV prehydration (2000 mL of saline within 12
ours before and after CM application) significantly
revented a decline in GFR after contrast exposure com-
ared with hydration given only during CM exposure
300 mL of).12
Another issue in CIN prophylaxis has been the use of
ydration with or without sodium bicarbonate. Bicarbon-
te is thought to prevent CIN by alkalinizing the urine,
hereby protecting against CIN induced free radical dam-
ge to the renal tubules. Merten et al found that the
ncidence of CIN was significantly lower in patients who
eceived bicarbonate compared with those who did not
1.7% vs 13.6%, P  .02).13 Silva et al conducted a litera-
ure review as well as a small randomized study assessing the
ffectiveness of bicarbonate in preventing CIN. While the
iterature review “strongly suggested” a protective effect of
odium bicarbonate, the randomized study failed to show a
ignificant difference in efficacy between 0.9% saline solu-
ion alone and a solution of 1.3% sodium bicarbonate.
ephropathy (CIN). The pathogenesis of CIN is linked to
(CM). Renal vasoconstriction is mediated by contrast-
smolality of CM. Vasodilators such as nitric oxide (NO)
such as tetrahydrobiopterin, the modification of NO
synthesis through nuclear factor KB (NFKB).29 This
medullary ischemia, hypoxia, and eventual endothelial
t this vasoconstriction. NAC increases NO production,
ilates and increases renal plasma flow. CM alters the
n of reactive oxygen species and apoptosis. NAC acts as
rotects against free radical damage.13ced n
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Volume 54, Number 2 Rundback et al 577consisted of a relatively small sample size (n 27) and that
no patients in either group developed CIN. The authors
concluded that the small number of patients did not allow
definite conclusions.28
Contrast osmolarity. Studies are conflicted as to
whether low-osmolar or iso-osmolar CM is more beneficial
in preventing CIN. Aspelin et al, in the NEPHRIC trial,
found that CIN was less likely to develop when iso-osmolar
CM was used (iodixanol) rather than low-osmolar CM
(iohexol).14 However, a much larger study by Liss et al
Table I. Mehran scoring based on risk factors for CIN
Risk factor
Systolic blood pressure 80 mm Hg
Intra-arterial balloon pump
Congestive heart failure (class III/IV or history of pulmonary ede
Age 75-years-old
Hematocrit level (39% for men and 35% for women)
Diabetes
Contrast media volume
Renal insufficiency
Risk score Risk o
5 or less 7.
6-10 14.
11-16 26.
16 57.
CIN, Contrast-induced nephropathy; GFR, glomerular filtration rate.
Table II. Incidence and risk of CIN with different therape
Study Infusate(s)
Solomon et al9 (1994) 0.45 saline  mannitol
0.45 saline  furosemide
0.45 saline
Taylor et al10 (1998) 0.45 saline at 75 mL/h
0.45 saline at 300 mL/h
Trivedi et al11 (2003) 0.9 saline administered 12 h befo
12 h after CM administration
Hydration with unrestricted oral
Bader et al12 (2004) 0.9 saline administered 12 h befo
12 h after CM administration
300 mL saline bolus given during
exposure
Merten et al13 (2004) 154 mEq/L sodium bicarbonate
154 mEq/L sodium chloride
Tepel et al17 (2000) NAC
Allaqaband et al18 (2002) NAC
Briguori et al19 (2002) NAC
Diaz-Sandoval et al20 (2002) NAC
Durham et al21 (2002) NAC
Shyu et al22 (2002) NAC
Kay et al23 (2003) NAC
CI, Confidence interval; CIN, contrast-induced nephropathy; NAC, N-aceinvolving over 57,000 patients, showed that the risk for leveloping acute renal failure and dialysis was higher when
atients received the iso-osmolar iodixanol vs the low-osmolar
edia ioxaglateor iohexol.Akeydifference fromtheNEPHRIC
rial was that this study evaluated rehospitalization of pa-
ients for acute renal failure rather than SCr levels as a
arker for CIN (Table III).15
Acetylcysteine (NAC). NAC is thought to protect
gainst CIN via direct antioxidant effect (preventing
ree-radical damage) and also by increasing NO produc-
ion. This increase in NO is thought to reverse the medul-
Point value
5
5
5
4
3
3
1 point for each 100 mL given
4 points for serum creatinine 1.5 g/dL
2 points for GFR of 40-60 mL/min/1.73 m2
4 points for GFR of 20-40 mL/min/1.73 m2
6 points for GFR of 20 mL/min/1.73 m2
Risk of dialysis
0.04%
0.12%
1.09%
12.8%
strategies
Incidence of
CIN in
treated
group
Incidence of
CIN in
control group Relative risk
28% — —
40%
11%
11.1% — —
5.6%
d 3.7% — —
34.6%
d 5.3% — —
15%
1.7% — —
13.6%
2% 21% 0.11 (95% CI, 0.02-0.86)
18% 15% 1.18 (95% CI,
7% 10% 0.59 (95% CI, 0.22-1.57)
8% 45% 0.18 (95% CI, 0.04-0.72)
26% 22% 1.20 (95% CI, 0.55-2.63)
3% 25% 0.14 (95% CI, 0.03-0.57)
4% 12% 0.32 (95% CI, 0.11-0.96)
eine.ma)
f CIN
5%
0%
1%
3%utic
re an
fluids
re an
CMary renal vasoconstriction associated with CM.
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August 2011578 Rundback et alA meta-analysis by Birck et al compared seven studies
that looked at the role of NAC in CIN prevention (Table
II). Through a random-effects model, the researchers con-
cluded that NAC provided a 56% relative risk reduction of
CIN in patients with renal insufficiency undergoing con-
trast procedures.16
Hoffman et al, however, cited the fact that most studies
use SCr as a measure of renal function and postulated that
NAC does not alter GFR but rather causes a decrease in SCr
levels through another mechanism. They found that NAC
caused no significant change in levels of cystatin C. Because
serum cystatin C concentrations are independent of age,
gender, and muscle mass, they concluded that measuring
SCr to assess renal function when assessing the role of NAC
might be misleading.24
Fenoldopam. Fenoldopam is a selective dopamine D1
agonist, causing vasodilatation of both renal and systemic
vessels. It is thought to protect against contrast-mediated re-
nal vasoconstriction and increase renal plasma flow (RPF).
Kini et al looked at CIN incidence in patients who
received IV fenoldopam during and after angiography (in
addition to saline hydration) vs patients who received hy-
dration only (n  159). The incidence of CIN was 4.7%
when fenoldopam was given, compared with 18.8% in the
control group (P .001). Notably, IV administration may
cause clinically significant hypotension (due to its systemic
vasodilatory effects) limiting its widespread use.25
Targeted renal therapy (TRT)with fenoldopam. TRT
refers to the delivery of therapeutic medications directly to
the kidneys via the renal arteries. This intrarenal (IR)
drug administration improves the therapeutic window by
increasing intrarenal drug concentration and reducing
systemic effects. The Benephit Infusion Catheter (Angiody-
namics, Queensbury, NY) is a bifurcated infusion cathe-
ter that allows TRT during coronary or peripheral cathe-
terization to reduce CIN risk in patients with renal
insufficiency.
Tierstein et al compared the effect of TRT vs IV
fenoldopam administration on GFR, RPF, plasma fenoldo-
pam levels, and systolic blood pressure. Patients who re-
ceived TRT had significantly higher RPF, GFR, and nadir
systolic blood pressure than those who received IV
fenoldopam. TRT was also associated with lower systemic
Table III. Odds ratios for developing renal failure after ad
ioxaglate (modified from reference 15)
Subset Contrast m
No previous renal history Iodixa
Ioxag
Previous renal failure Iodixa
Ioxag
Diabetic patients Iodixa
Ioxag
Patients requiring dialysis after CM exposure Iodixa
Ioxag
CI, Confidence interval; CM, contrast media.plasma drug concentration and a 25% change in GFR vevel 2 hours after CM administration (compared with a
14% change with IV administration).26
The Benephit System Renal Infusion Therapy (Be–RITe!)
ulticenter Registry was a postmarket registry that fol-
owed patients treated using the Benephit systems for TRT.
total of 501 patients were enrolled who were considered
igh risk for developing CIN during angiography. In pa-
ients who received TRT with fenoldopam (n  285), the
ncidence of CIN was 71% lower than predicted (8.1%
ctual CIN vs 28.0% predicted; P  .0001). Also, it was
hown that higher drug doses and longer duration of TRT
ere more effective (Table IV).27
ISCUSSION
CIN remains a substantial problem because of the mag-
itude of patients receiving contrast-enhanced imaging stud-
es. Although the overall reported prevalence of CIN varies
epending on definition and the timing of measurement, the
dverse impact on CIN on short- and long-termmortality are
ell studied.Thus, strategies arewarranted tomitigateCIN in
igh-risk populations, particularly patients with baseline renal
nsufficiency with or without diabetes mellitus. Although
here remains some controversy about the best preventive
pproach, a preponderance of level 2 data supports the routine
se of prehydration. As suggested by Mueller et al,8 intrave-
ous normal saline volume supplementation reduces the haz-
rd of CIN, is relatively cost-effective and safe, and should be
onsidered in all patients undergoing procedures with intra-
istration of iso-osmolar iodixanol vs low-osmolar
m Odds ratio 95% CI P value
1 — —
0.48 (0.39-0.58) .001
1 — —
0.54 (0.34-0.86) .009
1 — —
0.59 (0.40-0.86) .007
1 — —
0.48 (0.24-0.96) .039
able IV. TRT with fenoldopam: Effect of dosing and
uration on incidence of CIN10,27
Risk of CIN (based
on Mehran score)
Actual incidence
of CIN
RT administration of
0.2 g/kg/min
fenoldopam 28.3% 33.3% (P  .79)
RT administration of
0.4 g/kg/min
fenoldopam 26.9% 3.0% (P  .0001)
RT duration 60 min 26.5% 29.1% (P  .99)
RT duration 60 min 27.2% 2.8% (P  .001)
IN, Contrast-induced nephropathy; TRT, targeted renal therapy.min
ediu
nol
late
nol
late
nol
late
nol
lateascular contrast.
11
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 2 Rundback et al 579Other strategies to reduce CIN have variable or con-
flicting levels of evidence. In terms of contrast osmolarity,
the NEPHRIC trial found that iso-osmolar CM may be
better than low-osmolar CM in preventing CIN.14 How-
ever, a much larger study done by Liss et al15 demonstrated
disparate results. The use of NAC may prevent significant
increases in SCr in patients with chronic renal insufficiency
undergoing contrast procedures. However, because NAC
may be simply lowering the SCr without actually prevent-
ing renal damage, future studies should address the issue of
reduction of morbidity and mortality rates with this agent.
Evidence supports the role of fenoldopam on improving
renal function, although IV administration should be used
with caution due to the potential for hypotension. TRT
appears to improve safety and efficacy, although larger
randomized trials are needed to ensure intermediate and
long-term benefit.
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